Clinical Cancer Research Submission Guide: Requirements & Timeline

This page is about package readiness before upload.

Use it to decide:

• whether the manuscript package is strong enough for editorial screening

• what should already be visible in the title, abstract, cover letter, and first figures

• what needs to be fixed before the paper enters the system

If you are still deciding whether Clinical Cancer Research is the right journal at all, use the fit verdict page. If the paper is already submitted and you need to understand silence, triage, or review movement, use the Clinical Cancer Research submission process page instead.

Before the portal matters, the package should already make three things easy to see:

• what clinical or translational oncology question the paper actually changes

• why the evidence supports more than a basic-mechanism claim

• why the manuscript belongs in Clinical Cancer Research rather than a more basic or narrower oncology venue

If those answers still depend on long explanation from the authors, the package is probably not ready yet.

Clinical Cancer Research accepts Research Articles, Research Briefs, Resource Reports, Reviews (mostly commissioned), Perspectives, Regulatory Science and Policy articles, and Letters to the Editor. The journal uses AACR's SmartSubmit system for all submissions and requires every clinical trial to be registered and its registration number to be included.

• Core requirements:

• Word limit: 5,000 words of text for Research Articles, 2,500 for Research Briefs (size recommendations)

• Figure limit: 6 tables and/or figures for Research Articles, 4 for Research Briefs

• Clinical trial registration required for interventional studies

• Clinical trial manuscripts should state the primary objective, eligibility criteria, measured endpoints, and statistical approach and analysis

• CONSORT guidelines compliance for randomized trials

The editorial team screens submissions quickly for clinical relevance and translational impact. Papers advance to peer review only if they demonstrate clear patient implications beyond basic cancer mechanism.

Time to first decision can vary with reviewer matching and study complexity, but the more important point is that the bar for translational clarity is high. Well-designed studies with real clinical logic are much more likely to survive screening.

Clinical Cancer Research occupies a specific niche in the AACR journal family. While Cancer Research focuses on fundamental cancer biology and mechanisms, Clinical Cancer Research demands direct clinical application and patient relevance.

• Primary focus areas:

• Biomarker discovery and validation studies

• Drug resistance mechanisms with therapeutic implications

• Immunotherapy response and resistance patterns

• Precision medicine approaches and companion diagnostics

• Clinical trial results with mechanistic insights

• Pharmacokinetic and pharmacodynamic studies

The journal doesn't publish basic cancer biology unless it includes clear translational endpoints. Cell line studies alone won't make the cut. You need patient samples, clinical correlations, or direct therapeutic applications.

• Article types breakdown:

Research articles (5,000 words) cover comprehensive studies with multiple experimental approaches. These typically include preclinical validation followed by clinical correlation or early-phase trial results.

Research briefs (2,500 words) present focused findings that advance clinical understanding. These work well for biomarker studies, drug mechanism papers with clinical data, or preliminary clinical observations.

Review articles synthesize current clinical knowledge in specific cancer areas. The editorial team prefers reviews that identify gaps in clinical translation rather than comprehensive literature surveys.

• What differentiates it from Cancer Research:

Cancer Research wants mechanistic depth and basic biology insights. Clinical Cancer Research wants patient impact and clinical application. Cancer Research accepts pure laboratory studies. Clinical Cancer Research requires clinical correlation. The bar for clinical relevance is non-negotiable.

Clinical Cancer Research uses AACR's SmartSubmit system for submissions. The system walks you through required fields.

• Manuscript formatting:

• Pages and/or lines numbered

• Consecutive page numbering

• 12-point Arial, Helvetica, or Times New Roman font

• At initial submission AACR does not impose strict article size or formatting requirements; revised manuscripts must follow AACR's style page

• Required sections for research articles:

Title page includes all author information, affiliations, and corresponding author details. AACR asks for the Translational Relevance statement (120 to 150 words) on a page between the title page and the abstract. The main manuscript then has an abstract (250 words maximum), followed by introduction, methods, results, discussion, and references.

• Figure and table specifications:

For revised manuscripts, submit graphics as eps, tiff, ai, psd, png, or ps files (pdf and jpg are accepted for initial submissions only). Each figure needs a legend with a short title sentence and a description of the figure and data shown, including the number of technical and biological replicates. Complex or large tables go in as tabular supplementary data (xlsx or csv), and tables should not be included as part of a figure.

• Clinical trial documentation:

Manuscripts reporting human experimentation need statements of the ethical guidelines followed, institutional review board approval where appropriate, and informed consent. Clinical trials must be registered in a primary or partner registry of the WHO Registry Network (AACR's examples include ClinicalTrials.gov NCT numbers), and AACR asks for the registration number whenever a trial is mentioned in the text.

• Statistical requirements:

AACR requires enough detail on experimental design and statistical analysis for reviewers to assess the results, and a statistical analysis section in the Methods whenever statistical analysis is performed. For clinical trial manuscripts the journal asks for a clear statement of the primary objective, eligibility criteria, measured endpoints, and statistical approach, and reports of phase II trials should include a discussion of sample size calculations. We suggest reporting hazard ratios with confidence intervals for survival analyses and sensitivity and specificity for diagnostic biomarkers.

• Reference formatting:

Use numbered citations in the order of first mention. AACR's examples abbreviate journal names. Limit references to 50 for research articles and 20 for research briefs (size recommendations). With more than 6 authors, list the first 6 followed by et al.

• Cover letter requirements:

AACR strongly encourages a cover letter but does not specify required contents. We suggest it cover three elements: clinical significance statement, translational impact explanation, and conflict of interest disclosure. The editors look for clear articulation of how your findings change clinical practice or understanding.

• Supplementary materials:

Clinical protocols, additional statistical analyses, and extended methods go in supplementary files. Keep the main manuscript focused on clinically relevant findings. Supplementary data should support, not repeat, main text conclusions.

Size recommendations: Research Articles list 5,000 words of text excluding cover page, abstract, methods, tables, and references, with 6 tables and/or figures, a 250-word structured abstract, and a 120 to 150-word Translational Relevance statement (the AACR style page says 150 words, so the publisher's documents differ slightly). Research Briefs list 2,500 words, 4 tables and/or figures, and 20 references. AACR does not enforce these at initial submission.

• Day 0: SmartSubmit upload. AACR's SmartSubmit system accepts the package (manuscript with its display items, cover letter, supplementary data uploaded separately, and optional suggested reviewers and a suggested editor) and screens it for manuscript completeness and editorial integrity before editorial review.

• First editorial read. The editor judges how well the manuscript fits the journal's scope and its expectations of scientific excellence, importance, and impact on the wider cancer research community. AACR-wide, the median first decision without peer review was 3.8 days (average 4.4) for 2024 submissions.

• Peer review. AACR reports that more than 95% of peer-reviewed manuscripts are reviewed by two or more independent reviewers, and the AACR-wide median first decision after peer review was 35 days (average 37) for 2024 submissions.

• First editorial decision after review. The handling editor weighs the reviewers' comments and either renders a decision or recommends one to the Editor(s)-in-Chief.

• Revision and publication. Revised manuscripts need a detailed point-by-point response and a listing of all changes. After formal acceptance, AACR posts the accepted author manuscript online (OnlineFirst), usually within 48 hours, and sends page proofs approximately two to three weeks after the acceptance letter.

Clinical Cancer Research follows a two-stage editorial process: an early editorial screen followed by peer review for manuscripts that clearly fit the journal.

• Editorial screening phase:

The editorial team evaluates clinical relevance, translational potential, and scope fit. AACR does not publish a desk-rejection rate. Common reasons include insufficient clinical correlation, purely basic science findings, or scope mismatch.

• Peer review process:

Manuscripts that pass screening go to external reviewers; AACR reports that more than 95% of peer-reviewed manuscripts receive two or more independent reviewers, and the AACR-wide median first decision after peer review was 35 days for 2024 submissions. Reviewers focus on clinical significance, experimental rigor, and translational implications.

• Decision timeline:

First decisions often take longer than the initial editorial screen because translational papers need reviewer matching across both clinical and mechanistic expertise. Research briefs may move a little faster, but the real determinant is how clearly the manuscript fits the journal and how quickly reviewers can evaluate the core claim.

• Revision expectations:

Reviewers often request additional clinical validation, expanded patient cohorts, or clearer translational discussion. Be prepared to add clinical correlation experiments or collaborate with clinicians if your initial submission lacks patient data.

Accepted papers typically move online well before print scheduling. The exact production timeline matters less than whether the manuscript is framed strongly enough to make it through the translational bar in the first place.

Clinical Cancer Research rejection patterns cluster around a few recurring issues. Understanding these helps you self-assess before submitting and strengthens your revision strategy.

• Insufficient clinical correlation:

The most frequent rejection reason involves studies with interesting biology but no clear patient relevance. Cell line studies showing drug sensitivity don't guarantee publication unless you include patient samples, clinical trial data, or clear therapeutic implications.

• Solution: Include patient-derived samples, clinical databases, or collaborations with clinical researchers. If you can't access patient materials, partner with clinical groups or use publicly available clinical datasets to validate your findings.

• Weak translational rationale:

Papers that identify interesting targets or pathways but don't explain the path to clinical application face rejection. Editors want to see how your discovery connects to existing drugs, diagnostic tests, or clinical protocols.

• Solution: Research drugs in development that target your pathway. Reference similar biomarkers already in clinical use. Propose specific next steps for clinical translation, even if you're not doing those experiments yourself.

• Inadequate statistical power:

Clinical studies with small patient cohorts or underpowered analyses get rejected frequently. This particularly affects biomarker studies and survival analyses where statistical significance demands larger patient numbers.

• Solution: Calculate power requirements during study design. For retrospective studies, acknowledge limitations but provide effect size estimates. Consider multi-institutional collaborations to increase patient numbers.

• Missing clinical context:

Basic cancer biology studies occasionally get submitted without any clinical framing. These papers might be excellent science but don't fit the journal's mission.

• Solution: Before you start writing, ask how your findings could change clinical practice. If you can't answer that question convincingly, consider whether your paper is ready or if a different journal might be more appropriate.

• Poor clinical trial reporting:

Studies that don't follow CONSORT guidelines, lack proper registration, or have unclear endpoints face rejection. Clinical trial reporting standards are non-negotiable.

• Solution: Use CONSORT checklists during manuscript preparation. Register trials before patient enrollment. Clearly define primary and secondary endpoints in your methods section.

• Oversold clinical significance:

Authors sometimes claim broader clinical impact than their data supports. Reviewers and editors working in clinical settings quickly identify these overstatements.

• Solution: Be specific about your patient population and clinical context. Avoid phrases like "game-changing" or "paradigm-shifting." Let your data speak for itself.

Sometimes your manuscript doesn't align with Clinical Cancer Research's translational focus. Choosing the right journal saves time and increases your acceptance chances.

• For basic cancer mechanisms: Cancer Research accepts fundamental cancer biology without required clinical correlation. If your work focuses on novel pathways, cancer cell biology, or mechanistic studies, Cancer Research provides better scope alignment.

• For clinical trials and outcomes research: Journal of Clinical Oncology (JCO) specializes in clinical trial results, practice guidelines, and health services research. Phase III trials and practice-changing studies often fit better at JCO.

• For specific cancer types: Consider specialized journals like Breast Cancer Research, Lung Cancer, or Blood Cancer Journal for studies focused on particular malignancies. These journals often provide more targeted readership for specialized findings.

• For translational studies with broader appeal: Nature Medicine or Science Translational Medicine work for translational cancer studies with implications beyond oncology. These journals require higher impact and broader significance.

• For drug development focus: Cancer Discovery emphasizes therapeutic target identification and drug mechanism studies. If your work centers on novel therapeutics or drug resistance mechanisms, Cancer Discovery might provide better alignment.

• For immunotherapy and cancer immunology: Cancer Immunology Research, also published by AACR, focuses specifically on immune mechanisms in cancer. Immunotherapy studies often find more specialized readership there.

Before you upload, run your manuscript through a CCR submission readiness check to catch the issues editors filter for on first read.

• the paper is primarily basic cancer biology without clinical correlation, patient samples, or clinical datasets

• the clinical bridge depends on future studies rather than evidence present in the submitted figures and tables

• the manuscript is a single cell-line study without in vivo or clinical validation of the stated target

• the translational rationale is framed as future potential rather than demonstrated clinical consequence

This guide covers portal and policy. The fit call needs the manuscript itself. The review tells you whether your paper clears the Clinical Cancer Research fit check before upload, especially around translational claim stated in prose but absent in the data package, preclinical-only evidence without patient validation for the claim, and scope more suited to basic-science oncology than translational CCR. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

For manuscripts targeting Clinical Cancer Research, five patterns generate the most consistent desk rejections worth knowing before submission.

These five patterns come from our pre-submission review work. AACR's author instructions do not list desk-rejection triggers.

Translational claim stated in prose but absent in the data package

The Clinical Cancer Research categories of articles page says studies "must demonstrate a clear application to the current or future practice of medicine", and the About page describes the scope as "innovative clinical and translational cancer research studies that bridge the laboratory and the clinic." The application therefore has to be shown in the manuscript rather than promised in discussion prose.

In our pre-submission review work, we see many desk rejections involve manuscripts where the abstract or cover letter frames a finding as clinically actionable but the actual data rests entirely on cell line models without patient samples, clinical datasets, or validated in vivo evidence. Editors specifically screen for manuscripts where the clinical consequence is present in the figures, not only in the text.

Check whether your CCR translational claim is visible in the data →

Preclinical-only evidence without patient validation for the claim

We also often find many submissions report biomarker discovery or drug sensitivity findings in preclinical systems without the patient cohort data or clinical correlation needed to support the stated translational implication. In practice, editors consistently reject manuscripts where the primary evidence is from cell lines or animal models and the connection to patient outcomes is asserted rather than demonstrated, because Clinical Cancer Research's editorial standard requires clinical-level evidence to accompany mechanistic claims that carry direct therapeutic implications.

Check whether your preclinical evidence supports a CCR-level claim →

Scope more suited to basic-science oncology than translational CCR

A related pattern is that many submissions present mechanistic cancer biology findings as translational without a patient-facing component that would distinguish the work from what Cancer Research typically publishes. Editors consistently screen for manuscripts where the clinical or therapeutic consequence is the central contribution rather than a supporting context for a mechanistic story that would read more naturally in a basic-science oncology venue.

Check whether your manuscript is CCR fit or basic-oncology fit →

Clinical trial reporting or registration incomplete at submission

A related pattern is that many submissions involving human subjects arrive without complete CONSORT compliance, missing trial registration numbers from ClinicalTrials.gov or equivalent databases, or statistical analysis plans that do not match the stated primary endpoints. In our analysis of desk rejections at Clinical Cancer Research, this pattern is most common in early-phase clinical studies where reporting standards are applied inconsistently across the study protocol and the submitted manuscript.

Cover letter not stating the specific translational claim

A related pattern is that many submissions arrive with cover letters that describe the clinical importance of the cancer type without articulating what the study specifically found and how that finding changes a clinical or therapeutic decision for oncologists. Editors explicitly consider whether the cover letter makes the translational oncology case before routing the paper for specialist review.

SciRev author-reported review times and Clarivate 2026 JCR release bibliometric data provide additional benchmarks when planning your submission timeline.

Before submitting to Clinical Cancer Research, a Clinical Cancer Research submission readiness check identifies whether your translational evidence package, patient-facing data, and clinical significance meet the editorial bar before you commit to the submission.

Source limitations: AACR can update article-type limits, portal routing, trial-reporting requirements, and open-access policy after this review date, so authors should verify final administrative fields against the official AACR instructions before upload. Use this guide for the harder editorial decision the publisher page cannot answer: whether the manuscript's patient-facing evidence is strong enough for Clinical Cancer Research rather than a basic oncology, specialty oncology, or clinical-trial venue.

Method note: this page was reviewed against AACR Clinical Cancer Research journal materials, AACR author instructions and editorial-policy context, the local Clinical Cancer Research hub, and Manusights oncology pre-submission review patterns. It focuses on submission-guide and package-readiness questions.

The pattern we found in our pre-submission review work is not "more clinical language wins." It is that successful CCR manuscripts make the clinical decision, patient cohort, biomarker claim, or treatment implication visible before the reader reaches the Discussion.

Clinical Cancer Research receives submissions from researchers working at the intersection of laboratory discoveries and patient care. Published by the American Association for Cancer Research (AACR), it sits between basic cancer biology journals and purely clinical publications. Your manuscript needs to bridge that gap convincingly.

Master the cover letter process with our detailed template guide for any journal submission. For broader publication strategy, our journal selection framework helps match your research to the right venue. Before submitting anywhere, check our pre-submission readiness guide to avoid common timing mistakes.

Need expert feedback on your Clinical Cancer Research manuscript before submission? Manusights provides detailed pre-submission reviews from oncology specialists who understand what editors and reviewers look for.

A desk rejection costs weeks. A fit check costs one upload. See whether Clinical Cancer Research before I reformat is the right target for my abstract.

Worth reading alongside the author guidelines: Clinical Cancer Research formatting requirements.